Change Visitor Type



Oxford Capital exited its investment in Sirigen in August 2012. Sirigen was acquired by Becton, Dickinson and Company, a leading global medical technology company for $65 million.

Sirigen commercialised a novel application of conducting polymers in the medical diagnostics market. Sirigen’s technology adds “high sensitivity fluorescence” (HSF) to diagnostic techniques, as well as simplifying sample processing and instrumentation requirements. Generating sufficient signal from diagnostic tests, in order to be sure of an accurate diagnosis, is a key challenge for the diagnostic industry. By incorporating the light-harnessing power of the Sirigen polymers, the signal from the diagnostic is greatly increased.

  • Red Joan release date announced.

    Read more
  • What’s Brex’t for EIS and VCTs?

    Read more

  • News and Views

    The lastest industry news and views
    from our team at Oxford Capital.

    see more
  • raises Series B funding to expand industry-leading web data integration platform

    Read more
  • Grand Theft Auto documentary in the works from Salon Pictures, Independent

    Read more
  • Carey Mulligan, Andy Serkis, Daniel Kaluuya, Martin Freeman lead voice cast on ‘A Christmas Carol’ as Saboteur boards for AFM

    Read more
  • Stacy Martin Joins Gavin Rothery’s Sci-Fi Movie ‘Archive’

    Read more